VallerieVMcLaughlinMD
Cardiology • Ann Arbor, MIAdult Congenital Heart Disease
Professor, Internal Medicine, University of Michigan Medical School
Dr. McLaughlin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 E Medical Center Dr
Ann Arbor, MI 48109Phone+1 734-936-4000
Education & Training
McGaw Medical Center of Northwestern UniversityFellowship, Cardiovascular Disease, 1992 - 1995
University of MichiganResidency, Internal Medicine, 1989 - 1992- Northwestern University The Feinberg School of MedicineClass of 1989
Certifications & Licensure
MI State Medical License 1991 - 2025
IL State Medical License 1992 - 2005- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Fellow (FACC) American College of Cardiology
Clinical Trials
- Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) Start of enrollment: 2011 Jun 24
- Eisenmenger Quality Enhancement Research Initiative Start of enrollment: 2012 Jul 01
- Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument Start of enrollment: 2013 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsA new day has come: Sotatercept for the treatment of pulmonary arterial hypertension.Thomas M Cascino, Sandeep Sahay, Victor M Moles, Vallerie V McLaughlin
The Journal of Heart and Lung Transplantation. 2025-01-01 - Efficacy and Safety of Sotatercept Across Ranges of Cardiac Index in Patients with Pulmonary Arterial Hypertension: A Pooled Analysis of PULSAR and STELLAR.Mardi Gomberg-Maitland, David B Badesch, J Simon R Gibbs, Ekkehard Grünig, Marius M Hoeper
The Journal of Heart and Lung Transplantation. 2024-12-05 - Changes in REVEAL Lite 2 risk status are associated with long-term outcomes in patients with pulmonary arterial hypertension: A post-hoc analysis of the GRIPHON study.Raymond L Benza, Kelly M Chin, Sean Gaine, Nazzareno Galiè, Marius M Hoeper
The Journal of Heart and Lung Transplantation. 2024-12-01
Lectures
- Relieving the Pressure of Pulmonary Arterial Hypertension: Key Takeaways for the General Cardiologist Moving from Vague Symptoms to Ensuring Adequate Treatment Response2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
- Pulmonary Hypertension: From Etiology to Therapy2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
Authored Content
- Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for MortalityFebruary 2018
Press Mentions
ZENITH Trial Breakthrough: Winrevair Shows Significant Impact on Outcomes of Pulmonary Arterial HypertensionDecember 4th, 2024- Diagnosis and Treatment of Chronic Thromboembolic Pulmonary HypertensionSeptember 22nd, 2022
- Identifying and Navigating Challenging Clinical Scenarios in Pulmonary Arterial HypertensionAugust 25th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
